We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Brown Fat Hormone Signaling Prevents Obesity by Modulating Liver Lipid Metabolism

By LabMedica International staff writers
Posted on 25 Nov 2014
A hormone produced by brown adipose tissue has been determined to modulate the activity of liver cells that metabolize sugar into fats and is apparently linked to the development of metabolic disorders such as type II diabetes, nonalcoholic fatty liver disease, and obesity.

Investigators at the University of Michigan (Ann Arbor, USA) worked with genetically engineered mice in which the production of the hormone neuregulin 4 (Nrg4) was either blocked or enhanced. More...
The neuregulins, including NRG4, activate type-1 growth factor receptors to initiating cell-to-cell signaling through tyrosine phosphorylation.

In a paper published in the November 17, 2014, online edition of the journal Nature Medicine, the investigators reported that Nrg4 was highly expressed in adipose tissues, enriched in brown fat, and markedly increased during brown adipocyte differentiation. Adipose tissue Nrg4 expression was reduced in rodent and human obesity. Gain- and loss-of-function studies in genetically engineered mice demonstrated that Nrg4 protected against diet-induced insulin resistance and accumulation of fats in the liver by reducing lipogenic signaling.

Mice genetically engineered to lack the gene for NRG4 became obese and developed symptoms of type II diabetes and fatty liver disease. Animals in which NRG4 levels were genetically elevated were protected from these metabolic disorders when fed a high-calorie, high-fat diet.

Senior author Dr. Jiandie Lin, associate professor of cell and developmental biology at the University of Michigan, said, "In all models of obesity, NRG4 expression is reduced. We think obesity is a state of NRG4 deficiency. Realistically, there are still many challenges to figuring out how it acts in the body and might be used as a drug, but in general, we know that NRG4 is beneficial for body metabolism and are excited about its potential."

Related Links:

University of Michigan



New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.